Result of Oversubscribed Retail Offer
Proteome Sciences (AIM: PRM) is pleased to announce that the Retail Offer launched on 26 January 2026 has successfully completed and closed today at 12.00 p.m.
The Retail Offer was significantly oversubscribed. Accordingly, the Company has elected to increase the scale of the Retail Offer and has raised in aggregate £132,000 through the issuance of 7,542,856 Retail Offer Shares at an issue price of 1.75 pence per Retail Offer Share.
Retail Offer to raise up to £60,000
Proteome Sciences (AIM: PRM) is pleased to announce the launch of an offer to retail investors in the UK through BookBuild (the "Retail Offer") of up to 3,428,571 new ordinary shares of one penny each in the capital of the Company (“Retail Offer Shares”) at an issue price of 1.75 pence per Retail Offer Share (the "Issue Price") to raise up to £60,000.
£840,000 Fundraise and Retail Offer
Proteome Sciences (AIM:PRM) is pleased to announce that it has successfully raised gross proceeds of £840,000 (the “Fundraise”) through the issue of 48,000,000 ordinary shares of one penny each in the capital of the Company (the “Ordinary Shares”) to new and existing investors (the “Fundraise Shares”) at a price of 1.75 pence per Fundraise Share (the “Issue Price”).
Two further substantial contracts for Proteome Sciences
Proteome Sciences (AIM:PRM), is pleased to announce that following the Company’s announcement dated 8 December 2025, the Company has secured two further substantial Good Clinical Laboratory Practice (“GCLP”) contracts. The contracts have a combined value in excess of $1.5m. Trial samples are expected to be shipped in late Q1 this year, with the major part of the contracts completed in 2026.
Substantial contract for Proteome Sciences
Proteome Sciences (AIM:PRM), is pleased to announce that the Company has secured a third contract from a US biopharmaceutical company using the Company’s mass spectrometry services to develop a new assay at the company’s facilities in Frankfurt, Germany in anticipation of starting a new clinical trial programme next year.
Appointment of Nominated Adviser and Broker
Proteome Sciences (AIM:PRM), is pleased to announce that SP Angel Corporate Finance LLP has been appointed as the Company’s new Nominated Adviser and sole Broker with immediate effect
Interim results for the six months ended 30 June 2025
Proteome Sciences announces its unaudited interim results for the six months ended 30 June 2025
Result of Annual General Meeting (AGM)
The directors of Proteome Sciences are pleased to announce that at the Company's AGM, held at 12.00 noon today, all resolutions were duly passed.